Tygacil Use In Pregnancy & Lactation

Pregnancy: Tigecycline may cause fetal harm when administered to a pregnant woman. Results of animal studies indicate that tigecycline crosses the placenta and is found in fetal tissues. Decreased fetal weights in rats and rabbits (with associated delays in ossification) have been observed with tigecycline.
Tigecycline was not teratogenic in the rat or rabbit (see Pharmacology: Toxicology: Preclinical safety data under Actions).
There are no adequate and well-controlled studies of tigecycline in pregnant women. Tigecycline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Tigecycline has not been studied for use during labor and delivery.
Lactation: It is not known whether this drug is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of tigecycline/metabolites in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). Because many drugs are excreted in human milk, caution should be exercised when tigecycline is administered to a nursing woman (see Precautions).
Fertility: The effects of tigecycline on fertility in humans have not been studied. Nonclinical studies conducted with tigecycline in rats do not indicate harmful effects with respect to fertility or reproductive performance. (See Pharmacology: Toxicology: Preclinical safety data under Actions).